tirzepatide 2024 Diabetes drug linked to more significant weight loss than semaglutide Tirzepatide Once Weekly in Children

Human causation remains unproven, but the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2

PIONEER 10 Investigators

Mounjaro is a once-weekly injection containing tirzepatide, which targets two hormones, GLP-1 and GIP , and it's shown the strongest average weight loss results in clinical trials, at around 22.5% over 72 weeks

However, careful monitoring ensures that treatment remains both safe and comfortable

Our dedicated healthcare professionals are ready to provide personalized guidance to determine if tirzepatide is the right therapeutic choice for your unique medical journey

Outsourcing facilities operating under Section 503B had until March 19, 2025